Latest Breaking News On - பிராட் மைல்கள் - Page 1 : comparemela.com
HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
HUTCHMED Initiates a Japan Bridging Study to Support
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Share:
– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors –
– Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval –
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ( EMA ) has validated and accepted its marketing authorization application ( MAA ) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors ( NETs ). The EMA s validation confirms that the submission is sufficiently complete and that it is ready to commence the formal review process.
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.